Photo of Yiqiang (Eric) Cheng

View Scopus Profile

Yiqiang (Eric) Cheng, PhD

  • 2248 Citations
  • 26 h-Index
19982020

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Area of Expertise

The main focus of my research is to discover and develop bioactive natural products from microorganisms as drugs or drug leads for the treatment of cancer, infectious diseases, or other human medical conditions. In addition, I recently initiated a collaborative project for the engineering of novel oncolytic virus for cancer chemoimmunotherapy.
Key words: anti-aging, anti-cancer, anti-infective, crowd-sourcing, crowd-funding, drug discovery, drug development, natural product, synthetic biology, chemoimmunotherapy, contract service

Education/Academic qualification

BS in Microbiology, Huazhong Agricultural University

MS in Phytochemistry, Institute of Botany of the Chinese Academy of Sciences

PhD in Botany & Microbiology, Michigan State University

Fingerprint Dive into the research topics where Yiqiang (Eric) Cheng is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects

High-Resolution Tandem Mass Spectrometer for Advanced Biomolecular Research

Prokai, L., Forster, M. & Cheng, Y. (.

Intramural Research(UNTHSC)

27/01/17 → 31/01/18

Project: Research

Experimental Therapeutics Targeting Aberrant Alternative Splicing of Androgen Receptor Gene Expression in Castration Resistant Prostate Cancer

Cheng, Y. (.

UTSW Center for Translational Medicine

1/01/15 → 31/12/15

Project: Research

Discover and Engineer New Histone Deacetylase Inhibitors as Anticancer Agents

Cheng, Y. (.

NCI: National Cancer Institute

1/06/13 → 31/05/15

Project: Research

Discover and Engineer New Histone Deacetylase Inhibitors as Anticancer Agents

Cheng, Y. (.

1/08/10 → 31/05/11

Project: Research

Research Output

Overexpression of somatostatin receptor type 2 in neuroendocrine tumors for improved Ga68-DOTATATE imaging and treatment

Guenter, R., Aweda, T., Carmona Matos, D. M., Jang, S., Whitt, J., Cheng, Y. Q., Liu, X. M., Chen, H., Lapi, S. E. & Jaskula-Sztul, R., Jan 2020, In : Surgery (United States). 167, 1, p. 189-196 8 p.

Research output: Contribution to journal › Article

    • Origin and bioactivities of thiosulfinated FK228

    Liu, X., Currens, G. C., Xue, L. & Cheng, Y. Q., 1 Jan 2019, In : MedChemComm. 10, 4, p. 538-542 5 p.

    Research output: Contribution to journal › Article

    • Pulmonary carcinoid surface receptor modulation using histone deacetylase inhibitors

    Guenter, R. E., Aweda, T., Matos, D. M. C., Whitt, J., Chang, A. W., Cheng, E. Y., Liu, X. M., Chen, H., Lapi, S. E. & Jaskula-Sztul, R., Jun 2019, In : Cancers. 11, 6, 767.

    Research output: Contribution to journal › Article

    Open Access
    • 1 Scopus citations

    The ADEP biosynthetic gene cluster in Streptomyces hawaiiensis NRRL 15010 reveals an accessory clpP gene as a novel antibiotic resistance factor

    Thomy, D., Culp, E., Adamek, M., Cheng, E. Y., Ziemert, N., Wright, G. D., Sass, P. & Brötz-Oesterhelt, H., 1 Jan 2019, In : Applied and Environmental Microbiology. 85, 20, e01292-19.

    Research output: Contribution to journal › Article

    • 2 Scopus citations

    Chromobacterium spp. mediate their anti-Plasmodium activity through secretion of the histone deacetylase inhibitor romidepsin

    Saraiva, R. G., Huitt-Roehl, C. R., Tripathi, A., Cheng, Y. Q., Bosch, J., Townsend, C. A. & Dimopoulos, G., 1 Dec 2018, In : Scientific Reports. 8, 1, 6176.

    Research output: Contribution to journal › Article

    • 8 Scopus citations